Chiwetel Ejiofor is the latest name to be joining Tom Hardy in Venom 3. As reported by Deadline, the actor will be following up his appearance last year in Marvel Studios’ Doctor Strange in the Multiverse of Madness with a side-step across to Sony’s Universe of Spider-Man Characters.
Juno Temple was added to the Venom threequel last month, and while there are still no plot details available on who either star will be playing, it is expected that both characters will have a significant role in the film. The casting of Ejiofor is an interesting choice considering his major character appearance in the MCU and the way the two different universes have been seemingly crossing over in the wake of the multiverse opening up. Could he be reprising his role as Baron Mordo in some way, or will he be playing another character entirely? For now, we can only wait and find out.
MOVIEWEB VIDEO OF THE DAYSCROLL TO CONTINUE WITH CONTENT
The Venom franchise has been a box office hit for Sony, with the first two films grossing over a billion dollars worldwide. The success of the franchise can be attributed to its unique take on the antihero genre, with Tom Hardy’s portrayal of Eddie Brock/Venom receiving widespread praise.
Juno Temple’s rise to fame has been nothing short of meteoric. After working steadily in films and TV shows for over a decade, she finally got her breakthrough role in the popular TV series Ted Lasso. Her portrayal of the bubbly and optimistic Keeley Jones won her widespread critical acclaim. Temple’s involvement in Venom 3 is yet another indication of her impressive range as an actress. With her natural talent and infectious energy, she is sure to bring something special to the Venom franchise.
Meanwhile, Chiwetel Ejiofor has appeared in his own fair share of hits, including his Oscar nominated role in 12 Years a Slave, The Pod Generation with Emilia Clarke and upcoming movies Rob Peace and Charlize Theron’s Netflix sequel The Old Guard 2.
RELATED: Andy Serkis Addresses Why He’s Not Returning to Direct Venom 3
Venom 3 Is Currently in Pre-Production
Sony Pictures Releasing
Tom Hardy’s upcoming movie sequel, Venom 3 is in pre-production. The last time audiences saw Eddie Brock was in a post-credits scene in Spider-Man: No Way Home, where he and Venom briefly entered the MCU and then returned to their own universe, leaving behind a small amount of the symbiote. Hardy has previously expressed interest in expanding the Venom-Verse, which is Sony’s shared universe of Spider-Man villains, including characters like Morbius and Kraven the Hunter.
“Once it’s established, we then have to continue our Venom-verse,” Hardy explained. “But at the same time, we will always be looking to campaign to play with that with all the brothers and sisters who are out there, do you know what I mean? Whether we can connect the dots, that’s up to the constellations, and that’s above my pay grade, but we would be remiss not to think about that when we’re working on the material.”
Venom was released in 2018 and introduced the character of Eddie Brock, a journalist who is investigating experiments involving human trials. He is unknowingly merged with a symbiotic alien that has lethal abilities, and the fusion creates the antihero Venom. The movie explores the complex relationship between Eddie Brock and Venom, as they fight for control over Brock’s body. It was met with mixed reviews, but the commercial success of Venom paved the way for a sequel. Venom: Let There Be Carnage, directed by Andy Serkis, hit theaters in 2021 and reunited audiences with Eddie Brock and Venom. In this installment, Eddie tries to reignite his career by interviewing serial killer Cletus Kasady, who becomes the host of an alien symbiote named Carnage.
Venom 3 will be directed by Kelly Marcel, who previously worked on the scripts for Venom: Let There Be Carnage. Marcel is making her directorial debut with the movie, which marks a significant step in her career. Her involvement in the previous two movies suggests that Venom 3 will maintain the same tone and style as its predecessors.
You can view the original article HERE.
